title: ERCC1 expression as a predictive marker of cervical cancer treated with cisplatin-based chemoradiation.
abstract: OBJECTIVE
  The purpose of the present study was to evaluate the correlation between repair cross-complementing group-1 (ERCC1) status and the outcome of platin-based chemoradiation of locally advanced cervical cancer.
  
  
  METHODS
  Tumor specimens from 112 patients with locally advanced cervical cancer were evaluated for ERCC1 expression. The outcome of these patients was retrospectively assessed in correlation with ERCC1 expression.
  
  
  RESULTS
  Increased expression of ERCC1 correlates with a better prognosis of cervical cancer. The 2-year overall survival was 68.6% in the group with low H-score for ERCC-1 and gradually increased in the intermediate and high H-score groups to 71.7% and 90.7%, respectively.
  
  
  CONCLUSIONS
  The present study did not confirm the correlation of low levels of ERCC1 expression with unfavorable outcomes of patients with locally advanced cervical cancer treated with platin-based radiochemotherapy.
authors.affiliation: Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany. Mustafa-Zelal.Muallem@charite.de.
authors.forename: Mustafa Zelal
authors.initials: MZ
authors.lastname: Muallem
authors.forename: Simone
authors.initials: S
authors.lastname: Marnitz
authors.forename: Rolf
authors.initials: R
authors.lastname: Richter
authors.forename: Christhardt
authors.initials: C
authors.lastname: Köhler
authors.forename: Jalid
authors.initials: J
authors.lastname: Sehouli
authors.forename: Ruza
authors.initials: R
authors.lastname: Arsenic
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism / Q000401:mortality* / Q000628:therapy; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000401:mortality* / Q000628:therapy; D059248:Chemoradiotherapy / Q000401:mortality*; D002945:Cisplatin / Q000627:therapeutic use*; D004268:DNA-Binding Proteins / Q000378:metabolism*; D004720:Endonucleases / Q000378:metabolism*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008875:Middle Aged; D060787:Neoplasm Grading; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000378:metabolism / Q000401:mortality* / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; C071447:ERCC1 protein, human; D004720:Endonucleases; D002945:Cisplatin
keywords: ERCC1 protein; cervical cancer; chemoradiation; cisplatin; immunohistochemistry staining